| # | Drug | Count |
|---|---|---|
| 0 | NIRMATRELVIR AND RITONAVIR | 70 |
| 1 | ADALIMUMAB | 24 |
| 2 | DUPILUMAB | 21 |
| 3 | ACETAMINOPHEN | 17 |
| 4 | METHOTREXATE | 16 |
| 5 | METHOTREXATE SODIUM | 16 |
| 6 | PREDNISONE | 14 |
| 7 | CABOZANTINIB | 12 |
| 8 | INSULIN GLARGINE | 11 |
| 9 | LENALIDOMIDE | 11 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIRMATRELVIR AND RITONAVIR | 70 | 0.0013 |
| 1 | ELOTUZUMAB | 4 | 0.0008 |
| 2 | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 2 | 0.0007 |
| 3 | BUROSUMAB | 4 | 0.0006 |
| 4 | EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE | 2 | 0.0006 |
| 5 | CLADRIBINE | 5 | 0.0005 |
| 6 | GLUTAMINE | 2 | 0.0004 |
| 7 | IMIGLUCERASE | 2 | 0.0004 |
| 8 | LANTHANUM CARBONATE | 2 | 0.0004 |
| 9 | INSULIN GLARGINE-YFGN | 8 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 29 |
| 1 | Interleukin-4 Receptor alpha Antagonist [EPC] | 21 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 21 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 17 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 16 |
| 5 | Thalidomide Analog [EPC] | 14 |
| 6 | Vitamin C [EPC] | 14 |
| 7 | Insulin Analog [EPC] | 12 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 11 |
| 9 | Expectorant [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 1 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 4 | 0.0008 |
| 2 | Interferon gamma [EPC] | 1 | 0.0007 |
| 3 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 3 | 0.0003 |
| 4 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 1 | 0.0003 |
| 5 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] | 2 | 0.0003 |
| 6 | Interleukin-17A Antagonist [EPC] | 7 | 0.0002 |
| 7 | Autologous Cellular Immunotherapy [EPC] | 1 | 0.0002 |
| 8 | CD38-directed Cytolytic Antibody [EPC] | 1 | 0.0002 |
| 9 | Antisense Oligonucleotide [EPC] | 2 | 0.0002 |